Arca
Skip to content
Tools
Tools

IDH1, IDH2: IDH1/IDH2

Family in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on IDH1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Vorasidenib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        VorasidenibApprovedServierSmall moleculeInhibitorIDH1/IDH2 inhibitor19

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.VorasidenibPhase 3Not yet recruitingInstitut de Recherches Internationales ServierNov 17, 2026
        Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic CholangiocarcinomaVorasidenibPhase 2Not yet recruitingM.D. Anderson Cancer CenterNov 16, 2026
        A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)VorasidenibPhase 1Not yet recruitingHeidelberg UniversityOct 16, 2026
        Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseVorasidenibPhase 2RecruitingNuvation Bio Inc.Jul 14, 2026
        VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 MutationsVorasidenibPhase 1Not yet recruitingMegan ManticaJun 5, 2026
        Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy ComparedVorasidenib—RecruitingFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaApr 23, 2026
        Vorasidenib Guided by AGX PET in Recurrent/Low-grade GliomaVorasidenibNot applicableNot yet recruitingHuashan HospitalMar 13, 2026
        Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationVorasidenibPhase 2RecruitingInstitut de Recherches Internationales Servier (I.R.I.S.)Dec 16, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4523659, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.